Concepedia

Eliot Sugarman

ES

17

Publications

1.2K

Citations

15

H-Index

1997

Active since

Affiliations

Pfizer (United States)(Current)

Sanford Burnham Prebys Medical Discovery Institute

Wayne State University

University of Kansas

Eliot Sugarman is an author at Pfizer (United States) specializing in medicine, pharmacology, and biochemistry.

Top concepts

Publications per year

1997–2019

17

Publications

17

Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein

Ronald W. Clark, Tamara A. Sutfin, Roger B. Ruggeri et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2004 · 371 citations · Full text

Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits

Lee A. Morehouse, Eliot Sugarman, Patricia-Ann K. Bourassa et al. · Journal of Lipid Research · 2007 · 170 citations · Full text

Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1

Robert L. Dow, Jiancheng Li, Michael P. Pence et al. · ACS Medicinal Chemistry Letters · 2011 · 100 citations · Full text

, , +16

Comparison of synthetic saponin cholesterol absorption inhibitors in rabbits: evidence for a non-stoichiometric, intestinal mechanism of action

Lee A. Morehouse, F.W. Bangerter, Michael P. DeNinno et al. · Journal of Lipid Research · 1999 · 71 citations · Full text

MondoA coordinately regulates skeletal myocyte lipid homeostasis and insulin signaling

Byung Yong Ahn, Mangala M. Soundarapandian, H Sessions et al. · Journal of Clinical Investigation · 2016 · 69 citations · Full text

Rows per page

1–5 of 17